WordNet

be a contributing factor; "make things factor into a companys profitability"
any of the numbers (or symbols) that form a product when multiplied together
an independent variable in statistics
anything that contributes causally to a result; "a number of factors determined the outcome"
consider as relevant when making a decision; "You must factor in the recent developments" (同)factor in, factor out
resolve into factors; "a quantum computer can factor the number 15" (同)factor in, factor out
an event known to have happened or something known to have existed; "your fears have no basis in fact"; "how much of the story is fact and how much fiction is hard to tell"
a concept whose truth can be proved; "scientific hypotheses are not facts"
a piece of information about circumstances that exist or events that have occurred; "first you must collect all the facts of the case"
a statement or assertion of verified information about something that is the case or has happened; "he supported his argument with an impressive array of facts"
put into a good mood (同)humour
the trait of appreciating (and being able to express) the humorous; "she didnt appreciate my humor"; "you cant survive in the army without a sense of humor" (同)humour, sense of humor, sense of humour
(Middle Ages) one of the four fluids in the body whose balance was believed to determine your emotional and physical state; "the humors are blood and phlegm and yellow and black bile" (同)humour
the quality of being funny; "I fail to see the humor in it" (同)humour
of or relating to bodily fluids

PrepTutorEJDIC

(…の)『要因』,(…を生み出す)要素《+『in』+『名』(do『ing』)》 / 囲数,約数 / 代理人,《おもに英》仲買人 / =factorize
〈C〉『事実』,実際にある(あった)事 / 〈U〉真相,真実(truth) / 《the~》(法律用語で)犯行

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/11/16 13:25:35」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 原発性の体液性免疫不全：概要 primary humoral immunodeficiencies an overview
2. 血友病患者における第VIIIおよび第IX因子阻害物質 factor viii and factor ix inhibitors in patients with hemophilia
3. 直接トロンビン阻害剤および直接Xa因子阻害剤による抗凝固療法 anticoagulation with direct thrombin inhibitors and direct factor xa inhibitors
4. 複合免疫不全 combined immunodeficiencies
5. 糸球体の免疫障害の機序 mechanisms of immune injury of the glomerulus

English Journal

A high IL-4 production diplotype is associated with an increased risk but better prognosis of oral and pharyngeal carcinomas.

Yang CM, Chen HC, Hou YY, Lee MC, Liou HH, Huang SJ, Yen LM, Eng DM, Hsieh YD, Ger LP.Author information Department of Dentistry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; Department of Dental Laboratory Technology, Shu Zen College of Medicine & Management, Kaohsiung, Taiwan.AbstractOBJECTIVE: Interleukin (IL)-4 is a key cytokine in humoral and adaptive immunity. This study aimed to evaluate the association of IL-4 genetic variants (-590C>T and VNTR in intron 3) with the risk and prognosis of oral and pharyngeal squamous cell carcinoma (OPSCC).
Archives of oral biology.Arch Oral Biol.2014 Jan;59(1):35-46. doi: 10.1016/j.archoralbio.2013.09.010. Epub 2013 Oct 6.
OBJECTIVE: Interleukin (IL)-4 is a key cytokine in humoral and adaptive immunity. This study aimed to evaluate the association of IL-4 genetic variants (-590C>T and VNTR in intron 3) with the risk and prognosis of oral and pharyngeal squamous cell carcinoma (OPSCC).DESIGN: A total of 1215 subject
PMID 24169152

Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy.

Zavadova E, Vocka M, Spacek J, Konopasek B, Fucikova T, Petruzelka L.AbstractIn view of the fact that insufficiency in immune response often correlates with poor prognosis, research in recent years has focused on the task of describing the precise status and function of the immune system and its possible effect on cancer patients. Although more than two thirds of treated patients respond to endocrine therapy, most patients with metastatic breast cancer develop a resistance to it. Estrogen modulates angiogenesis, partially through its effects on vascular endothelial growth factor (VEGF). It also appears that transforming growth factor-beta (TGF beta) could be another factor contributing to this resistance. TGF beta is a highly immunosuppressive factor that inhibits natural and specific immunity against tumors and stimulates the production of VEGF. The purpose of the study was to monitor immune responses in patients with hormone receptor-positive breast cancer who were resistant to hormone therapy. The examination of cellular components (CD4, CD8, HLA-DR, NK cells) and humoral immunity (IgG, IgG subclasses, IgA, IgM,). TGF beta and VEGF production were monitored with special attention, along with an analysis of the changes that occurred during the hormonal treatment. 68 patients included in the research project were implemented with routine cancer treatment with endocrine therapy. Basic parameters (the histological type and grade, the degree of expression of estrogen receptors (ER) and progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), and the proliferative marker) were established. Patients were evaluated by a cancer clinical immunologist to exclude immune disorders, allergic or autoimmune origin. TGF beta and VEGF were measured by ELISA and antitumor cellular immunity (CD4, CD8) was measured by flow cytometry. Patients who failed in the first line of hormone therapy treatment were considered as resistant to hormone therapy.Depression in cellular immunity was found especially in patients with resistance to endocrine therapy. In addition, immunoglobulin plasma levels were decreased (mainly IgG4 subtype). Most patients showed clinical symptoms of immunodeficiency (frequent infections of respiratory or urinary tract, herpetic infections). Significant increases in TGF beta and VEGF plasma were also detected.The correlation of these factors with resistance to hormonal therapy and the state of anticancer immunity could be helpful in the task of predicting resistance to hormonal therapy and could contribute to the selection of targeted immune therapy in cancer patients in the future. Keywords: Breast cancer; immunodeficiency; TGF beta; VEGF.
Neoplasma.Neoplasma.2014;61(1):90-8.
In view of the fact that insufficiency in immune response often correlates with poor prognosis, research in recent years has focused on the task of describing the precise status and function of the immune system and its possible effect on cancer patients. Although more than two thirds of treated pat
PMID 24195514

Deficiency of innate and acquired immunity caused by an IKBKB mutation.

Pannicke U, Baumann B, Fuchs S, Henneke P, Rensing-Ehl A, Rizzi M, Janda A, Hese K, Schlesier M, Holzmann K, Borte S, Laux C, Rump EM, Rosenberg A, Zelinski T, Schrezenmeier H, Wirth T, Ehl S, Schroeder ML, Schwarz K.Author information From the Institute for Transfusion Medicine, University Hospital Ulm (U.P., C.L., H.S., K.S.), the Institute of Physiological Chemistry (B.B., T.W.), the Center for Biomedical Research, Genomics Core Facility (K. Holzmann), University of Ulm, and the Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service Baden-Wuerttemberg-Hessen (E.-M.R., H.S., K.S.), Ulm; the Center of Chronic Immunodeficiency, University Medical Center Freiburg (S.F., P.H., A.R.-E., K. Hese, M.R., A.J., M.S., S.E.), the Faculty of Biology, University of Freiburg (S.F.), the Center for Pediatrics and Adolescent Medicine (P.H., S.E.), and the Department of Rheumatology and Clinical Immunology (M.S.), University Hospital Freiburg, Freiburg; and the Translational Center for Regenerative Medicine, University of Leipzig, Leipzig (S.B.) - all in Germany; the Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm (S.B.); and the Department of Pediatrics, University of Saskatchewan, Saskatoon (A.R.), and the Departments of Biochemistry and Medical Genetics (T.Z.) and Pediatrics and Child Health (T.Z., M.L.S.), University of Manitoba, Winnipeg - both in Canada.AbstractBACKGROUND: Severe combined immunodeficiency (SCID) comprises a heterogeneous group of heritable deficiencies of humoral and cell-mediated immunity. Many patients with SCID have lymphocyte-activation defects that remain uncharacterized.
The New England journal of medicine.N Engl J Med.2013 Dec 26;369(26):2504-14. doi: 10.1056/NEJMoa1309199.
BACKGROUND: Severe combined immunodeficiency (SCID) comprises a heterogeneous group of heritable deficiencies of humoral and cell-mediated immunity. Many patients with SCID have lymphocyte-activation defects that remain uncharacterized.METHODS: We performed genetic studies in four patients, from fou
PMID 24369075

Japanese Journal

肝臓からのシグナルによる膵島制御機構 (特集膵島機能に関するControversy)

今井淳太,片桐秀樹
内分泌・糖尿病・代謝内科 39(2), 139-145, 2014-08
NAID 40020189416

ACE阻害薬とARBの使い分け

川井真,吉村道博
循環器内科 75(2), 200-210, 2014-02
NAID 40019987376

Folliculostellate Cells Are Required for Laminin Release from Gonadotrophs in Rat Anterior Pituitary

Tsukada Takehiro,Fujiwara Ken,Horiguchi Kotaro,Azuma Morio,Ramadhani Dini,Tofrizal Alimuddin,Batchuluun Khongorzul,Maliza Rita,Syaidah Rahimi,Kikuchi Motoshi,Yashiro Takashi
ACTA HISTOCHEMICA ET CYTOCHEMICA 47(5), 239-245, 2014
… These results suggest that a humoral factor from FS cells is required for laminin release from gonadotrophs. …
NAID 130004700245